CCS secures £1.3 million of investment in seed round

Cambridge Communication Systems Limited (CCS) today announced that it has raised over £1 million of investment to fund early stage deployments of its unique small-cell microwave backhaul system. The funding round was led by Cambridge Angels Founder Robert Sansom, who will become Chairman of CCS, and is backed by Cambridge Wireless Chairman David Cleevely as well as Imperial Innovations, Cambridge Angels and Cambridge Capital Group.

CCS is developing a low cost, high performance solution to the problem of backhaul in small-cell mobile communications networks. Small-cell networks are accepted as the only realistic solution to the pressing data capacity problem in mobile communications, but as yet no credible solution for backhaul – the transfer of data between these networks and the core infrastructure – has been developed. CCS’s technology is a unique self-organizing, self-optimizing multipoint-to-multipoint microwave communications system which operates in cheap and plentiful licensed spectrum. It is easy to deploy and maintain, has a small physical footprint, and can be rapidly scaled.

CCS was founded by Steve Greaves and John Porter both experienced entrepreneurs who were co-founders of Adaptive Broadband Limited and Cambridge Broadband Networks Limited.

“CCS is an exciting new investment for the Cambridge Angels, Imperial Innovations and Cambridge Capital Group” commented Robert Sansom, “with a strong founding team and a number of experienced technology investors.”.

Steve Greaves, Chief Executive Officer of Cambridge Communication Systems Ltd, also commented:

“We are very pleased to welcome our new investors to this exciting venture and are particularly pleased to welcome Robert Sansom as our Chairman. Our unique solution to the problem of cost effective small-cell backhaul has generated a great deal of interest and support from key operators within the mobile industry. This round of investment allows us to complete the development of our system and move forward to early-stage trials.”

Copyright © 2019 CCS Ltd     Privacy policy     Terms of purchase Designed & Developed by Onespacemedia

Tel: +44 1223 314 197